PepGen Shares Rise 92.9% After Phase 2 Myotonic Dystrophy Results

PepGen (NASDAQ: PEPG) shares rose 92.9% from Monday’s close to $4.61 at the Nov. 10 close after the company announced Phase 2 results for an experimental myotonic dystrophy treatment. The FREEDOM2-DM1 study is evaluating PGN-EDODM1 for myotonic dystrophy type 1. Among six participants receiving 10 mg/kg, mean muscle RNA splicing correction reached 46.5% at week 13. Five participants had more than 20% correction, and four had more than 50%. A pooled placebo group of four participants from two dose cohorts averaged 6.8% correction. At week 16, video hand-opening time, a measure of myotonia, improved by 3.9 seconds from baseline. The company also reported gains in hand grip strength, timed mobility and walking tests. Patient-reported measures were inconclusive at that point.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.